SG170612A1 - Antineoplastic combinations - Google Patents
Antineoplastic combinationsInfo
- Publication number
- SG170612A1 SG170612A1 SG200600623-3A SG2006006233A SG170612A1 SG 170612 A1 SG170612 A1 SG 170612A1 SG 2006006233 A SG2006006233 A SG 2006006233A SG 170612 A1 SG170612 A1 SG 170612A1
- Authority
- SG
- Singapore
- Prior art keywords
- antineoplastic combinations
- antineoplastic
- combinations
- ekb
- cci
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/16—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and unsaturated
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31064601P | 2001-08-07 | 2001-08-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG170612A1 true SG170612A1 (en) | 2011-05-30 |
Family
ID=23203475
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG200600623-3A SG170612A1 (en) | 2001-08-07 | 2002-08-06 | Antineoplastic combinations |
Country Status (27)
Country | Link |
---|---|
US (4) | US6617333B2 (uk) |
EP (2) | EP1414438B1 (uk) |
JP (2) | JP2005505549A (uk) |
KR (1) | KR20040029406A (uk) |
CN (3) | CN1326523C (uk) |
AR (2) | AR036250A1 (uk) |
AT (1) | ATE314069T1 (uk) |
AU (2) | AU2002330994B2 (uk) |
BR (1) | BR0211769A (uk) |
CA (1) | CA2455126A1 (uk) |
CY (1) | CY1104983T1 (uk) |
DE (1) | DE60208385T2 (uk) |
DK (1) | DK1414438T3 (uk) |
EA (2) | EA011098B1 (uk) |
ES (1) | ES2252512T3 (uk) |
HK (1) | HK1061204A1 (uk) |
HU (1) | HUP0401089A3 (uk) |
IL (2) | IL159859A0 (uk) |
MX (1) | MXPA04001118A (uk) |
NO (2) | NO325503B1 (uk) |
NZ (3) | NZ542272A (uk) |
PL (1) | PL368303A1 (uk) |
SG (1) | SG170612A1 (uk) |
TW (2) | TWI300351B (uk) |
UA (1) | UA77200C2 (uk) |
WO (1) | WO2003020266A1 (uk) |
ZA (1) | ZA200401801B (uk) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050124608A1 (en) * | 2001-04-03 | 2005-06-09 | Redmond H. P. | Treatment of cancers |
US20030027818A1 (en) * | 2001-04-03 | 2003-02-06 | Redmond H. Paul | Treatment of cancers |
US8304390B2 (en) * | 1997-07-31 | 2012-11-06 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US20060199811A1 (en) * | 1997-07-31 | 2006-09-07 | Pfirrmann Rolf W | Method of treatment for preventing or reducing tumor growth in the liver of patient |
US7892530B2 (en) * | 1999-06-04 | 2011-02-22 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of tumor metastases and cancer |
US8030301B2 (en) * | 1999-06-04 | 2011-10-04 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Treatment of cancers with methylol-containing compounds and at least one electrolyte |
US7345039B2 (en) * | 1999-06-04 | 2008-03-18 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer |
TWI286074B (en) | 2000-11-15 | 2007-09-01 | Wyeth Corp | Pharmaceutical composition containing CCI-779 as an antineoplastic agent |
LT3351246T (lt) | 2001-02-19 | 2019-07-10 | Novartis Pharma Ag | Rapamicino darinys, skirtas kieto naviko, susijusio su nereguliuojama angiogeneze, gydymui |
TWI233359B (en) * | 2001-04-06 | 2005-06-01 | Wyeth Corp | Pharmaceutical composition for treating neoplasm |
TWI296196B (en) * | 2001-04-06 | 2008-05-01 | Wyeth Corp | Antineoplastic combinations |
ATE427948T1 (de) | 2001-04-24 | 2009-04-15 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
US20020198137A1 (en) * | 2001-06-01 | 2002-12-26 | Wyeth | Antineoplastic combinations |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
JP4814520B2 (ja) * | 2002-05-15 | 2011-11-16 | エンドサイト,インコーポレイテッド | ビタミン−マイトマイシン結合体 |
US20040122048A1 (en) * | 2002-10-11 | 2004-06-24 | Wyeth Holdings Corporation | Stabilized pharmaceutical composition containing basic excipients |
CL2004000016A1 (es) * | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
AU2004210136C1 (en) | 2003-01-27 | 2010-10-07 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
UA83484C2 (uk) * | 2003-03-05 | 2008-07-25 | Уайт | Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція |
MXPA05010582A (es) * | 2003-04-22 | 2005-11-23 | Wyeth Corp | Combinaciones antineoplasicas. |
KR20060054412A (ko) * | 2003-08-01 | 2006-05-22 | 와이어쓰 홀딩스 코포레이션 | 암 치료 및 억제용 표피 성장인자 수용체 키나제 억제제와세포독성제의 배합물 용도 |
AR046194A1 (es) * | 2003-11-04 | 2005-11-30 | Mayo Foundation | Metodo de tratamiento del linfoma de celulas del manto |
AR046639A1 (es) * | 2003-11-21 | 2005-12-14 | Schering Corp | Combinaciones terapeuticas de anticuerpo anti- igfr1 |
PL1701698T3 (pl) * | 2004-01-08 | 2008-03-31 | Wyeth Corp | Prasowana bezpośrednio kompozycja farmaceutyczna do podawania doustnego CCI-779 |
PA8621501A1 (es) * | 2004-01-16 | 2005-08-10 | Wyeth Corp | Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos |
US20070281041A1 (en) * | 2004-03-02 | 2007-12-06 | Introgen Therapeutics, Inc. | Compositions and Methods Involving MDA-7 for the Treatment of Cancer |
AR047988A1 (es) * | 2004-03-11 | 2006-03-15 | Wyeth Corp | Combinaciones antineoplásicas de cci-779 y rituximab |
EP1789391B1 (en) * | 2004-07-23 | 2017-06-28 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
KR20070070184A (ko) * | 2004-10-28 | 2007-07-03 | 와이어쓰 | 자궁근종의 치료에 있어서 mTOR 억제제의 용도 |
NZ556673A (en) * | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
CN102357104B (zh) | 2005-03-07 | 2016-01-27 | 罗巴斯研究机构 | 粘液瘤病毒与雷帕霉素的组合在治疗性处理中的应用 |
CN101175757B (zh) * | 2005-03-16 | 2012-11-14 | 恩多塞特公司 | 蝶酸及其缀合物的合成和纯化 |
CN101180269A (zh) * | 2005-05-25 | 2008-05-14 | 惠氏公司 | 制备3-氰基-喹啉的方法和由其制得的中间体 |
WO2006127203A2 (en) * | 2005-05-25 | 2006-11-30 | Wyeth | Methods of synthesizing 6-alkylaminoquinoline derivatives |
RU2007143161A (ru) * | 2005-05-25 | 2009-07-10 | Вайет (Us) | Способы синтеза замещенных 3-цианохинов и их продуктов |
CN101252931A (zh) * | 2005-06-24 | 2008-08-27 | 惠氏公司 | 用于治疗癌症的4-苯胺基-3-喹啉甲腈 |
CA2613053C (en) * | 2005-07-01 | 2015-11-24 | Wyeth | Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarbonitrile and methods of preparing the same |
US20080280937A1 (en) * | 2005-08-19 | 2008-11-13 | Christopher Paul Leamon | Ligand Conjugates of Vinca Alkaloids, Analogs, and Derivatives |
KR101364912B1 (ko) * | 2005-08-19 | 2014-02-21 | 엔도사이트, 인코포레이티드 | 복수-약제 리간드 공액체 |
AU2016259316B2 (en) * | 2005-11-04 | 2018-09-06 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/or HKI-272 |
AU2006311877A1 (en) | 2005-11-04 | 2007-05-18 | Wyeth Llc | Antineoplastic combinations with mTOR inhibitor, herceptin, and/orHKI-272 |
AU2013204788B2 (en) * | 2005-11-04 | 2016-12-08 | Wyeth Llc | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
JP2009516671A (ja) | 2005-11-21 | 2009-04-23 | ノバルティス アクチエンゲゼルシャフト | mTOR阻害剤を使用する神経内分泌腫瘍処置 |
DE102006011507A1 (de) * | 2006-03-14 | 2007-09-20 | Lts Lohmann Therapie-Systeme Ag | Wirkstoffbeladene Nanopartikel auf Basis hydrophiler Proteine |
US20080119463A1 (en) * | 2006-11-16 | 2008-05-22 | Wyeth | 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML) |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
WO2008121467A2 (en) * | 2007-02-28 | 2008-10-09 | Dana-Farber Cancer Institute, Inc. | Combination therapy for treating cancer |
CA2680535C (en) * | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
TW200901989A (en) * | 2007-04-10 | 2009-01-16 | Wyeth Corp | Anti-tumor activity of CCI-779 in papillary renal cell cancer |
ES2732879T3 (es) | 2007-06-25 | 2019-11-26 | Endocyte Inc | Conjugados que contienen enlazantes espaciadores hidrófilos |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
US20090076060A1 (en) * | 2007-09-17 | 2009-03-19 | Protia, Llc | Deuterium-enriched temsirolimus |
US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
WO2009055562A1 (en) | 2007-10-25 | 2009-04-30 | Endocyte, Inc. | Tubulysins and processes for preparing |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
ES2968373T3 (es) | 2008-08-04 | 2024-05-09 | Wyeth Llc | Combinaciones antineoplásicas de neratinib y capecitabina |
WO2010063630A2 (en) * | 2008-12-02 | 2010-06-10 | Biocompatibles Uk Limited | Pancreatic tumour treatment |
JP5992325B2 (ja) | 2009-04-06 | 2016-09-14 | ワイス・エルエルシー | 乳癌のための、ネラチニブを活用する治療計画 |
KR101916481B1 (ko) | 2010-09-29 | 2018-11-07 | 인터벳 인터내셔널 비.브이. | N-헤테로아릴 화합물 |
HUE034347T2 (en) | 2010-09-29 | 2018-02-28 | Intervet Int Bv | N-heteroaryl compounds with a cyclic bridge unit for the treatment of parasitic diseases |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
CA2887727A1 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
US10274503B2 (en) | 2013-05-08 | 2019-04-30 | Vegenics Pty Limited | Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis |
US9242965B2 (en) * | 2013-12-31 | 2016-01-26 | Boehringer Ingelheim International Gmbh | Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors |
WO2017111076A1 (ja) | 2015-12-24 | 2017-06-29 | 協和発酵キリン株式会社 | α、β不飽和アミド化合物 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU415255A1 (ru) * | 1972-03-20 | 1974-02-15 | Т. А. Асонова, А. Я. Берлин, А. Б. Зезин, Е. Ф. Разводовский | СПОСОБ ПОЛУЧЕНИЯ р-БЕТАИ1ЮВВПТВci)iia aiisn^pii |
ZA737247B (en) | 1972-09-29 | 1975-04-30 | Ayerst Mckenna & Harrison | Rapamycin and process of preparation |
US3993749A (en) | 1974-04-12 | 1976-11-23 | Ayerst Mckenna And Harrison Ltd. | Rapamycin and process of preparation |
US4194050A (en) | 1976-04-30 | 1980-03-18 | Sumitomo Chemical Company, Limited | Process for producing an enamide |
US4195021A (en) | 1977-10-26 | 1980-03-25 | Eli Lilly And Company | 1,3-Disubstituted 2-azetidinone antibitotics |
US4193983A (en) | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US4885171A (en) | 1978-11-03 | 1989-12-05 | American Home Products Corporation | Use of rapamycin in treatment of certain tumors |
US5206018A (en) | 1978-11-03 | 1993-04-27 | Ayerst, Mckenna & Harrison, Inc. | Use of rapamycin in treatment of tumors |
US5066493A (en) * | 1978-11-03 | 1991-11-19 | American Home Products Corporation | Rapamycin in treatment of tumors |
US4401653A (en) | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
BE897134A (fr) | 1983-06-24 | 1983-12-27 | Solvay | Dienes polysubstitues |
US4478959A (en) | 1983-09-29 | 1984-10-23 | Air Products And Chemicals, Inc. | Amino and amido divalent metal carboxylates useful as catalysts for polyurethane formulations |
DE3347659A1 (de) | 1983-12-31 | 1985-07-11 | Bayer Ag, 5090 Leverkusen | Neue lackloesungen auf der basis von hydantoingruppen enthaltenden polymeren |
US4664825A (en) | 1984-10-25 | 1987-05-12 | The Lubrizol Corporation | Sulfurized compositions and lubricants containing them |
US5100899A (en) | 1989-06-06 | 1992-03-31 | Roy Calne | Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof |
CA2038633A1 (en) | 1990-03-20 | 1991-09-21 | Yoshimi Tsuchiya | Substituted amine derivatives having anti-hyperlipemia activity |
US5080899A (en) | 1991-02-22 | 1992-01-14 | American Home Products Corporation | Method of treating pulmonary inflammation |
US5078999A (en) | 1991-02-22 | 1992-01-07 | American Home Products Corporation | Method of treating systemic lupus erythematosus |
US5321009A (en) | 1991-04-03 | 1994-06-14 | American Home Products Corporation | Method of treating diabetes |
ATE135583T1 (de) | 1991-06-18 | 1996-04-15 | American Home Prod | Verwendung von rapamycin zur behandlung von t- zellen lymphom/leukämie bei erwachsenen |
IL102414A (en) | 1991-07-25 | 1996-08-04 | Univ Louisville Res Found | Medicinal preparations for the treatment of ocular inflammation, containing rapamycin |
CN1069492A (zh) * | 1991-08-21 | 1993-03-03 | 山之内制药株式会社 | 4-酰胺基咪唑衍生物 |
US5286730A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory disease |
US5286731A (en) | 1991-09-17 | 1994-02-15 | American Home Products Corporation | Method of treating immunoinflammatory bowel disease |
US5516781A (en) | 1992-01-09 | 1996-05-14 | American Home Products Corporation | Method of treating restenosis with rapamycin |
US5288711A (en) | 1992-04-28 | 1994-02-22 | American Home Products Corporation | Method of treating hyperproliferative vascular disease |
US5352783A (en) | 1993-06-09 | 1994-10-04 | Merck & Co., Inc. | Microbial transformation product having immunosuppressive activity |
US5362718A (en) | 1994-04-18 | 1994-11-08 | American Home Products Corporation | Rapamycin hydroxyesters |
US5561138A (en) | 1994-12-13 | 1996-10-01 | American Home Products Corporation | Method of treating anemia |
US5547948A (en) | 1995-01-17 | 1996-08-20 | American Home Products Corporation | Controlled release of steroids from sugar coatings |
US5496832A (en) | 1995-03-09 | 1996-03-05 | American Home Products Corporation | Method of treating cardiac inflammatory disease |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
EP1181013B1 (en) * | 1999-04-14 | 2006-10-11 | Dana-Farber Cancer Institute, Inc. | Method and composition for the treatment of cancer |
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
US6277983B1 (en) | 2000-09-27 | 2001-08-21 | American Home Products Corporation | Regioselective synthesis of rapamycin derivatives |
PT1318837E (pt) * | 2000-08-11 | 2004-12-31 | Wyeth Corp | Metodo de tratamenton de carcinoma positivo a receptor de estrogenio |
UA77200C2 (en) | 2001-08-07 | 2006-11-15 | Wyeth Corp | Antineoplastic combination of cci-779 and bkb-569 |
CL2004000016A1 (es) * | 2003-01-21 | 2005-04-15 | Wyeth Corp | Compuesto derivado de cloruro de 4-amino-2-butenoilo o una sal farmaceuticamente aceptable del mismo; procedimiento para preparar dicho compuesto, util como intermediario en la sintesis de compuestos inhibidores de proteina quinasa tirosina. |
-
2002
- 2002-06-08 UA UA2004031662A patent/UA77200C2/uk unknown
- 2002-08-02 TW TW091117467A patent/TWI300351B/zh active
- 2002-08-02 TW TW095110188A patent/TWI305527B/zh active
- 2002-08-06 AT AT02768432T patent/ATE314069T1/de not_active IP Right Cessation
- 2002-08-06 MX MXPA04001118A patent/MXPA04001118A/es active IP Right Grant
- 2002-08-06 NZ NZ542272A patent/NZ542272A/en unknown
- 2002-08-06 DK DK02768432T patent/DK1414438T3/da active
- 2002-08-06 US US10/212,889 patent/US6617333B2/en not_active Ceased
- 2002-08-06 SG SG200600623-3A patent/SG170612A1/en unknown
- 2002-08-06 IL IL15985902A patent/IL159859A0/xx unknown
- 2002-08-06 EP EP02768432A patent/EP1414438B1/en not_active Expired - Lifetime
- 2002-08-06 KR KR10-2004-7001883A patent/KR20040029406A/ko not_active Application Discontinuation
- 2002-08-06 EA EA200501251A patent/EA011098B1/ru not_active IP Right Cessation
- 2002-08-06 ES ES02768432T patent/ES2252512T3/es not_active Expired - Lifetime
- 2002-08-06 DE DE60208385T patent/DE60208385T2/de not_active Expired - Fee Related
- 2002-08-06 NZ NZ560845A patent/NZ560845A/en unknown
- 2002-08-06 WO PCT/US2002/024841 patent/WO2003020266A1/en active Application Filing
- 2002-08-06 AR ARP020102977A patent/AR036250A1/es unknown
- 2002-08-06 HU HU0401089A patent/HUP0401089A3/hu unknown
- 2002-08-06 BR BR0211769-0A patent/BR0211769A/pt not_active IP Right Cessation
- 2002-08-06 CN CNB028153480A patent/CN1326523C/zh not_active Expired - Fee Related
- 2002-08-06 PL PL02368303A patent/PL368303A1/xx unknown
- 2002-08-06 CN CNA2008100810681A patent/CN101279983A/zh active Pending
- 2002-08-06 CN CNB2006100025108A patent/CN100415753C/zh not_active Expired - Fee Related
- 2002-08-06 NZ NZ530847A patent/NZ530847A/en unknown
- 2002-08-06 JP JP2003524573A patent/JP2005505549A/ja not_active Withdrawn
- 2002-08-06 AU AU2002330994A patent/AU2002330994B2/en not_active Ceased
- 2002-08-06 EP EP05019642A patent/EP1671943A1/en not_active Withdrawn
- 2002-08-06 EA EA200400284A patent/EA006226B1/ru not_active IP Right Cessation
- 2002-08-06 CA CA002455126A patent/CA2455126A1/en not_active Abandoned
-
2004
- 2004-01-14 IL IL159859A patent/IL159859A/en not_active IP Right Cessation
- 2004-02-06 NO NO20040558A patent/NO325503B1/no not_active IP Right Cessation
- 2004-03-04 ZA ZA200401801A patent/ZA200401801B/en unknown
- 2004-06-15 HK HK04104313A patent/HK1061204A1/xx not_active IP Right Cessation
-
2005
- 2005-09-08 US US11/222,485 patent/USRE40418E1/en not_active Expired - Lifetime
- 2005-11-25 AR ARP050104937A patent/AR051778A2/es unknown
-
2006
- 2006-02-22 CY CY20061100255T patent/CY1104983T1/el unknown
- 2006-10-24 AU AU2006233165A patent/AU2006233165B2/en not_active Ceased
- 2006-12-22 US US11/645,327 patent/USRE41084E1/en not_active Expired - Fee Related
-
2007
- 2007-07-20 NO NO20073801A patent/NO20073801L/no not_active Application Discontinuation
- 2007-10-26 US US11/978,093 patent/USRE41253E1/en not_active Expired - Lifetime
-
2010
- 2010-01-22 JP JP2010011652A patent/JP2010155845A/ja active Pending
Non-Patent Citations (3)
Title |
---|
ö, VOGELÆS TEXTBOOK OF PRACTICAL ORGANIC CHEMISTRY, LONGMAN SCIENTIFIC * |
RECHERCHES SUR LES AMINOACIDES ET LEURS DERIVES. * |
THE COMBINED CHEMICAL DICTIONARY ON CD-ROM * |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG170612A1 (en) | Antineoplastic combinations | |
SG148031A1 (en) | Use of cci-779 as an antineoplastic agent | |
TW200503753A (en) | Antineoplastic combinations | |
HK1061212A1 (en) | Pyranoindazoles and their use for the treatment ofglaucoma | |
IL157898A0 (en) | Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil | |
GB0109537D0 (en) | Well treatment fluids and methods for the use thereof | |
NO20064130L (no) | Antineoplastiske kombinasjoner av CCI-779 og rituximab | |
HUP0400069A3 (en) | Pharmaceutical combinations and their use in preventing and treating the thrombosis | |
ZA200306232B (en) | Treatment involving DKK-1 or antagonists thereof. | |
SG153647A1 (en) | Antineoplastic combinations | |
AR033012A1 (es) | Combinaciones antineoplasicas | |
MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
ECSP034866A (es) | Combinaciones antineoplásticas | |
IL161501A0 (en) | Methods of preventing and treating flavivirus infection in animals | |
EG23929A (en) | Isoxazolines derivatives and their use as antidepressants | |
NZ525774A (en) | Use of SARP-1 for the treatment and/or prevention of scleroderma | |
AU2002234165A1 (en) | Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents | |
CA98963S (en) | Leg for table | |
AU2001292500A1 (en) | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain | |
AU2002364385A8 (en) | Implantable device and the use thereof | |
GB0012250D0 (en) | The treatment of intimal hyperplasia, and materials for use therein | |
WO2003030928A3 (en) | Antitumor preparation | |
GB0105742D0 (en) | Complexes and their use | |
AU2002214441A1 (en) | 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain | |
GB0116969D0 (en) | Neuro-phototransduction device and treatment |